- Primary research
- Open Access
Integrin β1 regulates the invasion and radioresistance of laryngeal cancer cells by targeting CD147
© The Author(s) 2018
- Received: 24 April 2018
- Accepted: 2 June 2018
- Published: 7 June 2018
Increased expression of integrin β1 has been reported to correlate with progression and therapy resistance in many types of cancers. The aim of this study was to investigate the effects of integrin β1 on the invasion and radioresistance of laryngeal cancer cells.
The expression of integrin β1 in the tumor specimens of laryngeal cancer patients was assessed by immunohistochemical assays. The invasion ability of laryngeal cancer cells was detected by transwell and wound healing assays. The radiosensitivity of laryngeal cancer cells was evaluated by flow cytometry and colony formation assays.
High expression of integrin β1 was significantly associated with lymph node metastasis, TNM stage and poor clinical outcomes (all p < 0.05). Knockdown of integrin β1 in laryngeal cancer cells inhibited invasion and increased radiosensitivity. Mechanistically, these effects were caused by suppression of the downstream focal adhesion kinase (FAK)/cortactin pathway. In addition, integrin β1 could interact with CD147 and the antibody blockade of CD147 led to the deactivation of FAK/cortactin signaling. Further studies revealed that the interaction between integrin β1 and CD147 relied on intact lipid rafts. Disruption of lipid rafts by methyl beta cyclodextrin in laryngeal cancer cells was able to reverse integrin β1-mediated malignant phenotypes.
Integrin β1 has potential as a therapeutic target in prevention and treatment of laryngeal cancer.
- Integrin β1
- Laryngeal cancer
Laryngeal cancer is a common respiratory cancer and is one of the leading causes of morbidity and mortality worldwide, especially in China [1, 2]. Because of limited therapeutic modalities, the prognosis of patients with laryngeal cancer after curative treatment remains unsatisfactory . The most common treatment options for laryngeal cancer are radiation therapy, surgery and chemotherapy. But patients often experience disease relapse due to eventual tumor metastasis and emergence of therapy resistance . Thus, there is an urgent need to identify new target molecules for improving treatment and overcoming therapy resistance of laryngeal cancer.
Integrins, a family of transmembrane cell surface receptors, are composed of 18 α and 8 β subunits . Integrins activate various signaling pathways, which contribute to the regulation of cell proliferation, migration, invasion, and therapy resistance [6, 7]. Integrin β1 is a critical regulator of cancer initiation and progression. In addition, integrin β1 has been linked to therapeutic resistance including conventional radiotherapy and chemotherapy in various tumor entities [8–11]. Aberrant integrin signaling has been implicated in laryngeal cancer metastasis . However, the underlying mechanisms of how the increased expression of integrin β1 confers invasion and radioresistance of laryngeal cancer remain unclear.
In this study, we first measured the expression of integrin β1 in the tumor specimens of laryngeal cancer patients. Next, we investigated the biological function of integrin β1 in modulating the invasion and radioresistance of laryngeal cancer cells. Lipid rafts are detergent-insoluble, cholesterol-rich microdomains of the plasma membrane . It is generally accepted that the localization of integrin β1 is lipid rafts-dependent . Here, we also evaluated the effects of lipid rafts on integrin β1-mediated malignant phenotypes. Our findings suggest a promising approach to treat laryngeal cancer by targeting integrin β1.
Clinical samples and immunohistochemistry
From 2010 to 2016, 60 laryngeal cancer tissues and 25 noncancerous laryngeal tissues were obtained from patients who underwent surgery at Taihe hospital, Hubei University of Medicine. The tissues were incubated with integrin β1 antibody (1:300; Abcam, Cambridge, MA, USA) at 4 °C overnight. After washing in PBS, the tissues were incubated with HRP-labeled secondary antibody (Beyotime, Jiangsu, China) for 30 min at room temperature. Finally, the specific immunostaining was visualized using an ultrasensitive streptavidin-peroxidase system (Maxim Biotech, Fuzhou, China) . The intensity of integrin β1 staining in individual cases was evaluated by two independent scorers in a blinded fashion. A score > 4 was defined as high expression, and a score ≤ 4 was regarded as low expression .
Cell culture and transfection
Sequences of integrin β1 siRNA and negative control siRNA
siRNA-1 (integrin β1-472)
siRNA-2 (integrin β1-2172)
siRNA-3 (integrin β1-2504)
Quantitative real-time PCR (qPCR) and western blotting
Total RNA was extracted using Trizol reagent (Invitrogen). And 1 µg of total RNA was reverse-transcribed into cDNA using a M-MLV RT kit (Takara, Dalian, China). QPCR was performed using the SYBR-Green Real-Time PCR Master Mix kit (Toyobo, Osaka, Japan). Primer sequences were as follows: integrin β1 (forward: 5′-GACGCCGCGCGGAAAAGATG-3′, reverse: 5′-GCACCACCCACAATTTGGCCC-3′) and GAPDH (forward: 5′-CCAACCGCGAGAAGATGA-3′, reverse: 5′-CCA GAGGCGTACAGGGATAG-3′). The relative mRNA expression of target genes was identified using 2−ΔΔCt methods. Western blotting was performed as described previously . In brief, 10 µg of total protein was isolated by 10% SDS-PAGE and transferred onto a PVDF membrane. After blocking with 5% non-fat dry milk, the membrane was incubated with primary antibodies. The following antibodies were purchased from Abcam and used in this study: integrin β1 (1:1000), CD147 (1:800), FAK (1:1000), Cortactin (1:1000), pFAK Y397 (1:1000), pCortactin Y421 (1:800), and GADPH (1:2000). The immunoreactive bands were detected using ECL-Plus chemiluminescence (Beyotime). GAPDH served as an internal control in the experiments.
Wound healing and transwell assays
For the wound healing migration assay, cells were plated in 24-well plates and allowed to attach overnight. Confluent monolayer cells were scraped using 10 µl pipette tips. At the indicated time points (0 and 48 h), the wound areas were photographed under a microscope (Olympus, Tokyo, Japan). For the transwell invasion assay, 1 × 105 cells were added into the upper chamber of an insert precoated with matrigel (Costar, Cambridge, MA, USA). And 100 μl medium containing 20% FBS were added to the lower part of the chamber. After 24 h of incubation, the invaded cells were fixed with methanol and stained with eosin solution (Beyotime).
The radiosensitivity of cells was determined by flow cytometry and colony formation assays. For cell cycle analysis, 1 × 106 cells treated with or without 4 Gy irradiation using an X-ray machine (X-RAD 320, Precision X-ray) were collected and stained with propidium iodide (PI; Beyotime). For cell apoptosis analysis, 1 × 106 cells treated with or without 4 Gy irradiation were stained with Annexin V-FITC (Beyotime) and PI according to the manufacturer’s protocol. The cell cycle distribution and apoptosis rate were measured using flow cytometry (Becton–Dickinson, Mountain View, CA, USA). For colony formation assay, cells were seeded in increasing numbers (200–6000 cells per 6 cm petri dish) before being irradiated. After 14 days, cells were fixed and stained for colony counting (colonies ≥ 50 cells). The surviving fractions were calculated and irradiations were performed as published previously .
Cells were incubated with or without MβCD (Sigma, St. Louis, MO, USA) for 1 h. Then cells were fixed with 5% formaldehyde, permeabilized with 0.2% Triton X-100, and blocked with 3% BSA. The cells were stained with integrin β1 antibody for 1 h, followed by incubation with Cy3-conjugated secondary antibody (Sigma) for 45 min. For lipid raft marker ganglioside GM1 labeling, cells were incubated with FITC-conjugated cholera toxin subunit B (CTXB, Sigma) for 1 h. Cell nuclei were counterstained with DAPI (Sigma). The colocalization between GM1 and integrin β1 was analyzed using the Olympus confocal software.
Isolation of lipid rafts
Lipid raft fractions were isolated using the Raft Isolation Kit (Sigma) following the manufacturer’s protocol . Twelve fractions were collected and subjected to western blotting. Fractions 1–4 were marked as raft fractions and fractions 5–12 were labeled as non-raft fractions .
Co-IP was performed as described previously . Briefly, cell lysates were incubated with the anti-integrin β1 or anti-CD147 antibody overnight at 4 °C. The antibody-protein conjugates were then incubated with protein A/G agarose beads (Thermo Fisher, Rockford, IL, USA) for 4 h at 4 °C. The reaction mixture was washed three times and boiled for 5 min at 100 °C. The samples were run on a 10% SDS-PAGE gel and blotted with the special antibody.
All experiments were performed in triplicate. All statistical analyses were carried out using SPSS 14.0 (SPSS Inc, Chicago, IL). A p value of < 0.05 was considered significant. All results were expressed as the mean ± SD. Statistical differences were calculated by Student’s t test or Chi square test.
High expression of integrin β1 in laryngeal cancer patients is associated with TNM stage, lymph node, and poor survival
Relationship between integrin β1 expression and clinicopathological parameters
No. of patients
Integrin β1 expression
Low (n = 24)
High (n = 36)
< 3 cm
≥ 3 cm
Grade of differentiation
Lymph node metastasis
I + II
III + IV
Integrin β1 plays a functional role in laryngeal cancer cell invasion and radioresistance
Inhibition of integrin β1 reduces invasiveness of laryngeal cancer cells
Inhibition of integrin β1 increases radiosensitivity of laryngeal cancer cells
Integrin β1 interacts with CD147 and regulates FAK/cortactin signaling
The interaction between integrin β1 and CD147 relies on intact lipid rafts
Disruption of lipid rafts inhibits the invasion and increases the radiosensitivity of laryngeal cancer cells
Laryngeal cancer is a highly aggressive malignant tumor with increasing incidence and poor prognosis. And, the emergence of resistance to therapy is a major obstacle in the treatment of laryngeal cancer patients. Exploring relevant factors related to tumorigenesis and development is urgently needed for laryngeal cancer treatment. In the present study, we found that integrin β1 was frequently overexpressed in clinical laryngeal cancer samples. Moreover, integrin β1 expression was correlated with various clinicopathological features including TNM stage and lymph node metastasis. Most importantly, high expression of integrin β1 in laryngeal cancer tissues was associated with poor survival. In addition, loss of function experiments showed that integrin β1 could regulate the invasion and radiosensitivity of laryngeal cancer cells. These results identified integrin β1 as a potential therapeutic target for laryngeal cancer.
Evidence has long accumulated to point toward a key role for integrin β1 in the control of cancer invasion. For example, integrin β1 was a critical effector in promoting the metastasis of esophageal squamous cell carcinoma . Regulation of integrin β1 by miR-199a-5p was involved in breast cancer invasion . Integrin β1 silencing could suppress COX-2-mediated cancer cell invasion in non-small-cell lung cancer . Similarly, our present study confirmed that high expression of integrin β1 was associated with laryngeal cancer invasion. We employed siRNA technology to suppress the expression of integrin β1 in laryngeal cancer cells. The in vitro assays showed that integrin β1 depletion reduced the invasiveness of laryngeal cancer cells.
To date, extensive studies have been performed to investigate the mechanisms of radioresistance in laryngeal cancer. And, a number of molecules have been suggested to be involved in the development of radioresistance. For instance, simultaneous inhibition of HIF-1α and GLUT-1 expression was able to increase the radiosensitivity of laryngeal cancer . MiR-503 might decrease the radioresistance of laryngeal cancer cells via the inhibition of WEE1 . Expression of hPOT1 was reported to be correlated with telomere length and radiosensitivity of laryngeal cancer cells . ALDH1 was shown to act as a predictor of radioresistance in laryngeal cancer . In this study, we demonstrated the role of integrin β1 in mediating the radiosensitivity of laryngeal cancer cells. It is well known that radiation caused apoptosis and induced G2/M cell cycle checkpoint arrest [10, 17]. Our study also revealed that the inhibition of integrin β1 significantly sensitized laryngeal cancer cells to radiation, induced cell apoptosis and reduced G2/M arrest after radiation.
Studies have shown that FAK/cortactin signaling plays important roles in integrin β1-mediated malignant phenotypes. For instance, integrin β1/FAK/cortactin signaling was essential for human head and neck cancer resistance to radiotherapy . Integrin β1/FAK signaling was associated with the invasion and migration of medulloblastoma . Our study confirmed that FAK/cortactin pathways could be suppressed by integrin β1-knockdown, implying their participation in the invasion and radioresistance of laryngeal cancer cells. We also demonstrated that the interaction of integrin β1 with CD147 could activate the downstream FAK/cortactin signaling pathway, subsequently enhancing the malignant properties of laryngeal cancer cells.
As a hallmark of tumor cells, metabolic alterations play a critical role in tumor development . Metabolic reprogramming is also required for both malignant transformation and tumor development, including invasion and metastasis . CD147 is ubiquitously expressed with the highest levels on metabolically active tumor cells and is able to form complex with three major types of transporters (CD98 heavy chain (CD98hc)-L-type amino acid transporter, ASCT2, and monocarboxylate transporters) as well as epithelial cell adhesion molecule (EpCAM) . As an interaction partner of CD147, EpCAM influences the microenvironment within tumors, especially the nutrient microenvironment . Considering that CD147 and its interaction proteins are essential for cellular metabolism, further experiments will be needed to reveal the underlying effects of integrin–CD147 complex and altered metabolism on invasion and radiosensitivity of laryngeal cancer cells.
Lipid rafts have been implicated in cancer cell apoptosis, adhesion and invasion [18, 34]. However, few studies have addressed the effects of lipid rafts on the invasion and radioresistance of laryngeal cancer cells. In the current study, we observed a significant association of integrin β1 with lipid rafts in laryngeal cancer cells using morphological methods and biochemical isolation of lipid raft fractions. We found that disruption of lipid rafts by MβCD did not influence the expression of integrin β1. These data were in line with the previous studies on the functional role of MβCD . In addition, disruption of lipid rafts could regulate the invasion and radiosensitivity of laryngeal cancer cells. Based on our results, it is possible that the intact lipid rafts might serve as a signaling platform for integrin β1.
In conclusion, our data provide strong evidence for the contribution of integrin β1 to the invasion and radioresistance of laryngeal cancer cells. Integrin β1 could interact with CD147 in laryngeal cancer cells. We also provide evidence that lipid rafts play important roles in integrin-β1-mediated malignant phenotypes. Therefore, integrin β1 has potential as a therapeutic target in prevention and treatment of laryngeal cancer.
LL designed and performed the experiments. XD and FP contributed the reagents, materials, and analysis tools. LS analyzed the data and wrote the paper. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Availability of data and materials
All data generated or analysed during this study are included in this article.
Consent for publication
Ethics approval and consent to participate
This study was approved by the Research Ethics Committee of Hubei University of Medicine (Hubei, China). All experiments were performed in accordance with the principles of the Declaration of Helsinki. All patients had signed informed consents.
This work was supported by the National Natural Science Foundation of China (81502666), the Natural Science Foundation of Hubei Province (2015CFA076), the Initial Project for Post-Graduates of Hubei University of Medicine (2016QDJZR10) and the Natural Science Foundation of Hubei Provincial Department of Education (B2017118).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.View ArticlePubMedGoogle Scholar
- Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.View ArticlePubMedGoogle Scholar
- Hamilton DW, Bins JE, McMeekin P, Pedersen A, Steen N, De Soyza A, et al. Quality compared to quantity of life in laryngeal cancer: a time trade-off study. Head Neck. 2016;38(Suppl 1):E631–7.View ArticlePubMedGoogle Scholar
- Lin CC, Fedewa SA, Prickett KK, Higgins KA, Chen AY. Comparative effectiveness of surgical and nonsurgical therapy for advanced laryngeal cancer. Cancer. 2016;122(18):2845–56.View ArticlePubMedGoogle Scholar
- Ahmed KM, Zhang H, Park CC. NF-kappaB regulates radioresistance mediated by beta1-integrin in three-dimensional culture of breast cancer cells. Cancer Res. 2013;73(12):3737–48.View ArticlePubMedPubMed CentralGoogle Scholar
- Gamble LJ, Borovjagin AV, Matthews QL. Role of RGD-containing ligands in targeting cellular integrins: applications for ovarian cancer virotherapy (Review). Exp Ther Med. 2010;1(2):233–40.View ArticlePubMedPubMed CentralGoogle Scholar
- Eke I, Deuse Y, Hehlgans S, Gurtner K, Krause M, Baumann M, et al. beta1 Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. J Clin Invest. 2012;122(4):1529–40.View ArticlePubMedPubMed CentralGoogle Scholar
- Carbonell WS, DeLay M, Jahangiri A, Park CC, Aghi MK. beta1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer Res. 2013;73(10):3145–54.View ArticlePubMedPubMed CentralGoogle Scholar
- Yuan J, Liu M, Yang L, Tu G, Zhu Q, Chen M, et al. Acquisition of epithelial–mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and beta1-integrin signaling pathway in tumor cells. Breast Cancer Res. 2015;17:69.View ArticlePubMedPubMed CentralGoogle Scholar
- Wu J, Li Y, Dang YZ, Gao HX, Jiang JL, Chen ZN. HAb18G/CD147 promotes radioresistance in hepatocellular carcinoma cells: a potential role for integrin beta1 signaling. Mol Cancer Ther. 2015;14(2):553–63.View ArticlePubMedGoogle Scholar
- Babel L, Grunewald M, Lehn R, Langhans M, Meckel T. Direct evidence for cell adhesion-mediated radioresistance (CAM-RR) on the level of individual integrin beta1 clusters. Sci Rep. 2017;7(1):3393.View ArticlePubMedPubMed CentralGoogle Scholar
- Klobucar M, Sedic M, Gehrig P, Grossmann J, Bilic M, Kovac-Bilic L, et al. Basement membrane protein ladinin-1 and the MIF-CD44-beta1 integrin signaling axis are implicated in laryngeal cancer metastasis. Biochim Biophys Acta. 2016;1862(10):1938–54.View ArticlePubMedGoogle Scholar
- Petersen EN, Chung HW, Nayebosadri A, Hansen SB. Kinetic disruption of lipid rafts is a mechanosensor for phospholipase D. Nat Commun. 2016;7:13873.View ArticlePubMedPubMed CentralGoogle Scholar
- Bi J, Wang R, Zhang Y, Han X, Ampah KK, Liu W, et al. Identification of nucleolin as a lipid-raft-dependent beta1-integrin-interacting protein in A375 cell migration. Mol Cells. 2013;36(6):507–17.View ArticlePubMedPubMed CentralGoogle Scholar
- Ai R, Sun Y, Guo Z, Wei W, Zhou L, Liu F, et al. NDRG1 overexpression promotes the progression of esophageal squamous cell carcinoma through modulating Wnt signaling pathway. Cancer Biol Ther. 2016;17(9):943–54.View ArticlePubMedPubMed CentralGoogle Scholar
- Shen L, Luo Z, Wu J, Qiu L, Luo M, Ke Q, et al. Enhanced expression of alpha2,3-linked sialic acids promotes gastric cancer cell metastasis and correlates with poor prognosis. Int J Oncol. 2017;50(4):1201–10.View ArticlePubMedGoogle Scholar
- Shen L, Dong XX, Wu JB, Qiu L, Duan QW, Luo ZG. Radiosensitisation of human glioma cells by inhibition of beta1,6-GlcNAc branched N-glycans. Tumour Biol. 2016;37(4):4909–18.View ArticlePubMedGoogle Scholar
- Raghu H, Sodadasu PK, Malla RR, Gondi CS, Estes N, Rao JS. Localization of uPAR and MMP-9 in lipid rafts is critical for migration, invasion and angiogenesis in human breast cancer cells. BMC Cancer. 2010;10:647.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang R, Bi J, Ampah KK, Zhang C, Li Z, Jiao Y, et al. Lipid raft regulates the initial spreading of melanoma A375 cells by modulating beta1 integrin clustering. Int J Biochem Cell Biol. 2013;45(8):1679–89.View ArticlePubMedGoogle Scholar
- Shen L, Dong X, Yu M, Luo Z, Wu S. beta3GnT8 Promotes gastric cancer invasion by regulating the glycosylation of CD147. J Cancer. 2017;8(2):314–22.View ArticlePubMedPubMed CentralGoogle Scholar
- Li Y, Wu J, Song F, Tang J, Wang SJ, Yu XL, et al. Extracellular membrane-proximal domain of HAb18G/CD147 binds to metal ion-dependent adhesion site (MIDAS) motif of integrin beta1 to modulate malignant properties of hepatoma cells. J Biol Chem. 2012;287(7):4759–72.View ArticlePubMedGoogle Scholar
- Xu Z, Zou L, Ma G, Wu X, Huang F, Feng T, et al. Integrin beta1 is a critical effector in promoting metastasis and chemo-resistance of esophageal squamous cell carcinoma. Am J Cancer Res. 2017;7(3):531–42.PubMedPubMed CentralGoogle Scholar
- Li W, Wang H, Zhang J, Zhai L, Chen W, Zhao C. miR-199a-5p regulates beta1 integrin through Ets-1 to suppress invasion in breast cancer. Cancer Sci. 2016;107(7):916–23.View ArticlePubMedPubMed CentralGoogle Scholar
- Pan J, Yang Q, Shao J, Zhang L, Ma J, Wang Y, et al. Cyclooxygenase-2 induced beta1-integrin expression in NSCLC and promoted cell invasion via the EP1/MAPK/E2F-1/FoxC2 signal pathway. Sci Rep. 2016;6:33823.View ArticlePubMedPubMed CentralGoogle Scholar
- Shen LF, Zhao X, Zhou SH, Lu ZJ, Zhao K, Fan J, et al. In vivo evaluation of the effects of simultaneous inhibition of GLUT-1 and HIF-1alpha by antisense oligodeoxynucleotides on the radiosensitivity of laryngeal carcinoma using micro 18F-FDG PET/CT. Oncotarget. 2017;8(21):34709–26.View ArticlePubMedPubMed CentralGoogle Scholar
- Ma H, Lian R, Wu Z, Li X, Yu W, Shang Y, et al. MiR-503 enhances the radiosensitivity of laryngeal carcinoma cells via the inhibition of WEE1. Tumour Biol. 2017;39(10):1010428317706224.View ArticlePubMedGoogle Scholar
- Lei H, Feng D, Zhou F, Xu H, Tang T, Yu H, et al. Expression of human protection of telomere 1 correlates with telomere length and radiosensitivity in the human laryngeal cancer Hep-2 cell line. Oncol Lett. 2015;10(2):1149–54.View ArticlePubMedPubMed CentralGoogle Scholar
- Martin M, Hinojar A, Cerezo L, Garcia J, Lopez M, Prada J, et al. Aldehyde dehydrogenase isoform 1 (ALDH1) expression as a predictor of radiosensitivity in laryngeal cancer. Clin Transl Oncol. 2016;18(8):825–30.View ArticlePubMedGoogle Scholar
- Nalla AK, Asuthkar S, Bhoopathi P, Gujrati M, Dinh DH, Rao JS. Suppression of uPAR retards radiation-induced invasion and migration mediated by integrin beta1/FAK signaling in medulloblastoma. PLoS ONE. 2010;5(9):e13006.View ArticlePubMedPubMed CentralGoogle Scholar
- Liang Y, Liu J, Feng Z. The regulation of cellular metabolism by tumor suppressor p53. Cell Biosci. 2013;3(1):9.View ArticlePubMedPubMed CentralGoogle Scholar
- Yoshida GJ. Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res. 2015;34:111.View ArticlePubMedPubMed CentralGoogle Scholar
- Xu D, Hemler ME. Metabolic activation-related CD147–CD98 complex. Mol Cell Proteomics. 2005;4(8):1061–71.View ArticlePubMedPubMed CentralGoogle Scholar
- Yoshida GJ, Saya H. EpCAM expression in the prostate cancer makes the difference in the response to growth factors. Biochem Biophys Res Commun. 2014;443(1):239–45.View ArticlePubMedGoogle Scholar
- Brandstaetter H, Kendrick-Jones J, Buss F. Myo1c regulates lipid raft recycling to control cell spreading, migration and Salmonella invasion. J Cell Sci. 2012;125(Pt 8):1991–2003.View ArticlePubMedPubMed CentralGoogle Scholar